Last reviewed · How we verify
Melan-A
At a glance
| Generic name | Melan-A |
|---|---|
| Sponsor | Istituto Superiore di Sanità |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site reaction
- Fatigue
- Headache
- Myalgia
- Nausea
- Chills
- Rash maculo-papular
- Arthralgia
- Anemia
- Pruritus
- Fever
- Injection site pain
Key clinical trials
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
- Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (PHASE1, PHASE2)
- Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye (PHASE2)
- flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer (PHASE2)
- Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma (PHASE2)
- Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 (PHASE1)
- A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence (PHASE2)
- Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melan-A CI brief — competitive landscape report
- Melan-A updates RSS · CI watch RSS
- Istituto Superiore di Sanità portfolio CI